While Alnylam Pharmaceuticals, Inc. ( NASDAQ:ALNY ) shareholders have enjoyed a good week with stock up 47%, they need...
Alnylam Pharmaceuticals (ALNY) and Alimera Sciences, Inc. (ALIM) are in the spotlight following study and merger updates, respectively.
Alnylam (ALNY) soars as its phase III study, seeking to expand Anvuttra's label to include the treatment of ATTR amyloidosis with cardiomyopathy, achieves primary and all secondary endpoints.